Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).
Phase of Trial: Phase I
Latest Information Update: 21 May 2012
At a glance
- Drugs VGX 3400 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 21 May 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov. (Parent trial: NCT01142362)
- 16 May 2012 Status changed from active, no longer recruiting to completed, according to an Inovio Pharmaceuticals media release.
- 30 Mar 2012 Planned end date changed from 1 Nov 2011 to 1 May 2012 as reported by ClinicalTrials.gov (Parent trial: NCT01142362).